Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Asclera

(Polidocanol)

Small molecule

BBoston Scientific Corporation

0

Indications

5

Total Trials

0

Active Trials

0

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

2

Patents

Clinical

Trials by Indication[1]

Treatment2 trials

Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst

Unknown status·—·Phase 4·NCT05798936·30 enrolled

An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst

Terminated·UUniversity of Edinburgh·Phase 4·NCT02154789·10 enrolled

Cutaneous Melanoma1 trial

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases

Withdrawn·MMelanoma Institute Australia·Phase 2·NCT03754140

Neurofibromatosis Type 11 trial

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Completed·MMassachusetts General Hospital·Phase 1·NCT06132165·13 enrolled

Combination Therapy1 trial

TENDOSHOCK-2010 Combination Therapy for Athletic Tendinopathies

Unknown status·HHannover Medical School·Phase 2·NCT01185951·114 enrolled

Regulatory

FDA Approval Timeline[3]

Mar 30, 2010

ASCLERA

NDA NDA021201

Dec 21, 2017

VARITHENA

NDA NDA205098

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Polidocanol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polidocanol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA205098). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Asclera. U.S. Food & Drug Administration.
[5]
SEC EDGAR — Boston Scientific Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: BBoston Scientific Corporation

Patent Landscape[4]

Patent Cliff

Nov 19, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7814943Nov 19, 2027

9480652May 12, 2032

Related News